CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 179 filers reported holding CRISPR THERAPEUTICS AG in Q2 2018. The put-call ratio across all filers is 3.04 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2020 | $8,583,000 | -11.2% | 56,058 | -51.5% | 0.38% | -10.5% |
Q3 2020 | $9,663,000 | -36.5% | 115,526 | -44.2% | 0.42% | -31.4% |
Q2 2020 | $15,220,000 | +158.4% | 207,105 | +49.1% | 0.61% | +88.9% |
Q1 2020 | $5,891,000 | -2.2% | 138,911 | +40.5% | 0.32% | +25.1% |
Q4 2019 | $6,023,000 | +115.2% | 98,888 | +107.6% | 0.26% | +346.6% |
Q2 2018 | $2,799,000 | – | 47,628 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |